LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

Home・Akcijų sąrašas・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

75.64 0.46

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

74.4

Max

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-100M -229M
Pardavimai	46M 203M
Pelno marža	-112.808
Darbuotojai	1,402
EBITDA	4.7B 4.6B

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+29.47% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-04-29

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-1.3B 12B
Ankstesnė atidarymo kaina	75.18
Ankstesnė uždarymo kaina	75.64

Naujienos nuotaikos

By Acuity

50%

146 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

29.78 / 33.645 Palaikymas ir pasipriešinimas

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-10 20:38; UTC

Uždarbis

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

2026-03-10 23:57; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-03-10 23:57; UTC

Rinkos pokalbiai

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

2026-03-10 23:47; UTC

Rinkos pokalbiai

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

2026-03-10 23:37; UTC

Įsigijimai, susijungimai, perėmimai

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

2026-03-10 23:37; UTC

Įsigijimai, susijungimai, perėmimai

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

2026-03-10 23:37; UTC

Įsigijimai, susijungimai, perėmimai

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

2026-03-10 23:37; UTC

Įsigijimai, susijungimai, perėmimai

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

2026-03-10 23:35; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

2026-03-10 23:06; UTC

Uždarbis

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

2026-03-10 22:51; UTC

Svarbiausios naujienos

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

2026-03-10 21:39; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

2026-03-10 21:21; UTC

Uždarbis

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

2026-03-10 21:15; UTC

Uždarbis

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

2026-03-10 21:15; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

2026-03-10 21:14; UTC

Uždarbis

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

2026-03-10 21:13; UTC

Uždarbis

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

2026-03-10 21:12; UTC

Uždarbis

Franco-Nevada 4Q Rev $597.3M >FNV

2026-03-10 21:12; UTC

Uždarbis

Franco-Nevada 4Q EPS $1.90

2026-03-10 20:57; UTC

Uždarbis

Oracle Stock Jumps on Earnings Beat -- Barrons.com

2026-03-10 20:50; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2026-03-10 20:44; UTC

Uždarbis

Oracle Stock Jumps on Earnings Beat -- Barrons.com

2026-03-10 20:34; UTC

Rinkos pokalbiai

Uždarbis

Global Equities Roundup: Market Talk

2026-03-10 20:34; UTC

Rinkos pokalbiai

Uždarbis

Oracle Building More Software for Less Money After Restructuring -- Market Talk

2026-03-10 20:23; UTC

Uždarbis

Oracle Stock Jumps on Earnings Beat -- Barrons.com

2026-03-10 20:16; UTC

Uždarbis

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

2026-03-10 20:14; UTC

Uždarbis

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

2026-03-10 20:14; UTC

Uždarbis

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

2026-03-10 20:13; UTC

Uždarbis

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

2026-03-10 20:12; UTC

Uždarbis

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

29.47% į viršų

12 mėnesių prognozė

Vidutinis 95.86 USD 29.47%

Aukščiausias 110 USD

Žemiausias 72 USD

Remiantis 15 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

15 ratings

Pirkti

Laikyti

Parduoti

Remiantis 15 analitikų, pateikusių Ionis Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

The bullish and bearish events are balanced.

All events are bullish.

All events are bearish.

Rinkos nuotaikos

By Acuity

146 / 351 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.